title: miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma.
abstract: Micro-RNAs are a group of small noncoding RNAs approximately 22 nucleotides in length. Recent work has shown differential expression of mature micro-RNAs in human cancers. We characterized the alteration in expression of miR-29b in ovarian serous carcinoma. miR-29b expression was analyzed using quantitative stem-loop reverse transcriptase polymerase chain reaction on a set of 50 formalin-fixed, paraffin-embedded ovarian serous carcinoma samples. Protein expression of p53, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67, and insulinlike growth factor 1 was quantified in the corresponding tissue microarray. The expression profile of miR-29b was correlated with clinicopathological and patient survival data. We provide definitive evidence that miR-29b is down-regulated in a significant proportion of ovarian serous carcinomas and is associated with specific clinicopathological features, most notably high miR-29b expression being associated with reduced disease-free survival.
authors.affiliation: Department of Histopathology, Trinity College, Dublin, Ireland. flavinr@tcd.ie
authors.forename: Richard
authors.initials: R
authors.lastname: Flavin
authors.forename: Paul
authors.initials: P
authors.lastname: Smyth
authors.forename: Ciara
authors.initials: C
authors.lastname: Barrett
authors.forename: S
authors.initials: S
authors.lastname: Russell
authors.forename: Hannah
authors.initials: H
authors.lastname: Wen
authors.forename: Jianjun
authors.initials: J
authors.lastname: Wei
authors.forename: Alex
authors.initials: A
authors.lastname: Laios
authors.forename: Sharon
authors.initials: S
authors.lastname: O'Toole
authors.forename: M
authors.initials: M
authors.lastname: Ring
authors.forename: K
authors.initials: K
authors.lastname: Denning
authors.forename: J
authors.initials: J
authors.lastname: Li
authors.forename: S
authors.initials: S
authors.lastname: Aherne
authors.forename: D
authors.initials: D
authors.lastname: Sammarae
authors.forename: N A
authors.initials: NA
authors.lastname: Aziz
authors.forename: A
authors.initials: A
authors.lastname: Alhadi
authors.forename: Sephen P
authors.initials: SP
authors.lastname: Finn
authors.forename: M
authors.initials: M
authors.lastname: Loda
authors.forename: Sheppard
authors.initials: S
authors.lastname: B
authors.forename: Orla
authors.initials: O
authors.lastname: Sheils
authors.forename: John J
authors.initials: JJ
authors.lastname: O'Leary
mesh_terms: D018284:Cystadenocarcinoma, Serous / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D035683:MicroRNAs / Q000096:biosynthesis* / Q000235:genetics; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: C532045:MIRN29a microRNA, human; D035683:MicroRNAs